Further to the request from the Combinations Alliancefor clarity on which drugs and areas of scientific interest are open for collaboration under the master terms of agreement, AstraZeneca/MedImmune are pleased to provide this detail as follows.

Any proposals that are of interest and that AZ/MedImmune and our Alliance partners would be keen to progress, will be reviewed by AZ/MedImmune internal governance in order to secure appropriate funding prior to a decision

AZD1775 (Wee1 inhibitor) Project representative:

  • Development stage - Phase II
  • Settings of interest :-
  • Monotherapy
  • Beyond ovarian, TNBC and SCLC- such as HER2+ breast cancer, gastric, lung, hemes
  • Combination with other DDR agents- including sequencing of drugs
  • Olaparib- Beyond ovarian, TNBC, SCLC such as prostate, pancreas, gastric, HNSCC
  • ATR
  • ATM
  • Other novel checkpoint agents
  • Combination with Immunotherapy
  • Beyond ovarian, TNBC, SCLC such as HNSCC, NSCLC, gastric, pancreas, bladder, HCC, and Hemes (MM, FL, AML, DLBCL)
  • Combination with Chemotherapy
  • Chemotherapy including novel chemotherapy and formulation developed chemotherapy- Including ovarian, TNBC, SCLC
  • Radiation
  • Novel/Novel Combinations- VEGF, mTor, AKT, etc
  • Other study designs
  • Neo-adjuvant
  • Radiation
  • Novel/Novel Combinations- VEGF, mTor, AKT, etc
  • Window studies
  • Maintenance
  • Sequencing studies
  • Basket approaches in DDR and others
  • Peadiatrics
  • Other special patient populations
  • Please contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to generate additional preclinical work to support clinical settings of interest.

AZD9150 (STAT3 Antisense oligonucleotide) Project representative:

  • Development stage - Phase II
  • Settings of interest -
  • Combination studies exploiting the emerging immunomodulatory role of AZD9150
  • Correlative studies to understand better the immunomodulatory role of AZD9150
  • Please contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to generate additional preclinical work to support clinical settings of interest.

AZD5069 (CXCR2 inhibitor) Project representative:

  • Development stage - Phase II
  • Settings of interest -
  • Combination studies exploiting the emerging role of CXCR2 and immunomodulatory role of AZD5069
  • Correlative studies to understand better the immunomodulatory role of AZD5069
  • Please contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to generate additional preclinical work to support clinical settings of interest.

AZD9496 (Selective oestrogen receptor downregulator) Project representative:

  • Development stage - Phase I
  • Settings of interest - In combinations with other novel targeted biological agents and other endocrine therapies – e.g. AI; Subgroups with ER+ Mutations
  • Monotherapy (e.g. 1st line endocrine naïve or receiving adjuvant endocrine therapy and later lines of therapy. As maintenance therapy after tumour stabilisation by chemotherapy)
  • Monotherapy and Combinations in Pre- and peri-menopausal women
  • ER+ endometrial or ovarian cancer may also be considered
  • Please contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to generate additional preclinical work to support clinical settings of interest.

Tagrisso [AZD9291] (EGFRm NSCLC). Project representative:

Development stage - Phase III & post launch

  • Settings of interest:
  • Second –lines and beyond
  • Disease management pathways
  • Characterization of ILD
  • Explore dose scheduling options
  • Local/regional practice variations
  • Measurement of unmet need
  • Adverse event management
  • Diagnostic Testing
  • First –Line Therapy
  • Primary resistance 1L
  • Uncommon EGFR mutations
  • Oligometastatic disease + SRS
  • Other resistance to 1L EGFR TKIs
  • Paired tumor/non-tumor resistance
  • Treatment beyond progression
  • Combinations
  • Targeted small molecules
  • Combination immunotherapies – current and novel
  • Vaccines
  • Combination VEGFR inhibitors
  • Sequencing studies
  • Earlier stages of NSCLC disease
  • Special Populations
  • Patients with CNS & LM disease
  • Primary or acquired resistance ≥ 2L
  • Elderly
  • Poor performance status
  • Germline T790M resistance
  • Other tumor types

1